Infections caused by septicemic strains of Salmonella are significant animal health as well as food safety concerns for the North American swine industry. Among the various strategies to control these mfections at the herd level, development of vaccines are attractive alternatives. In this study, based on previous studies of immune response to various protems following natural and experimental infections of pigs by Salmonella, we designed a subumt slow delivery vaccme and tested it m an experimental model of Infection. The selected 1mmunogen1c protem was cloned and purified by chromatography. The purified protein was then incorporated m PLGA (a polymer that is slowly degraded within the ammal's gastro Intestinal system) m1crospheres and g1ven orally once to groups of p1gs (n=8) while control animals (n=8) rece1ved only PBS. An1mals were challenged orally 4 weeks after the vaccmation w1th 1 0 8 cells of a virulent strains of Salmonella Typhimurium. An1mals were examined twice a day and climcal signs evaluated using a predetermmed sconng gnd. Pigs were sacrificed 12 days later and bacterial cultures of vanous organs, electron m1croscopy and evaluation of lgA response by ELISA were performed. No Significant difference was found at bactenology and ELISA but marked differences 1n climcal s1gns were observed between vaccinated and non vaccinated animals. None of vaccmated an1mals showed fever exceedmg 40°C while it was observed in 5 out of 8 non vaccinated Only one of vaccmated p1gs showed mild diarrhea wh1le severe diarrhea was observed m all control ammals Different s1zes of m1crospheres were observed m intestmal crypts of vacc1nated ammals at electron m1croscopy We concluded that th1s vaccine can protect p1gs aga1nst climcal s1gns associated with expenmental infection by Salmonella Typh1munum.
Introduction
Although Salmonella IS, m pigs, most often associated w1th sub-clinical 1nfect1ons, the Typhimurium serovar can cause severe clinical s1gns such as septicaemia and may as well result m mortalities that can have significant econom1cal 1mpacts 1n affected herds. This serovar is often among the most important serovar recovered from humans and 11 IS therefore cnllcal to reduce the number of affected ammals. When herds are affected by climcal outbreaks of S. Typh1munum, 11 was shown that the bactena IS present in most an1mals/pens and environmental samples (Letellier and al 1999) , increas1ng the likelihood of meat contammat1on. It is therefore important to control these infections at the herd level both for productivity and food safety po1nt of v1ews Since the host-adapted serovar Choleraesuis was in the past, and IS st1ll, assoc1ated w1th s1m1lar clin1cal s1gns, most vacc1nes, live or autogenous, were developed to protect pigs against this serovar Nevertheless, a few live vacc1nes were proposed to reduce S Typh1munum clinical s1gns (Roesler et al, 2004) In this study, we report the development of a sub-umt slow delivery vaccme aga1nst S Typh1munum 1n p1gs and results of a pre-clinical protect1on trial using an expenmental model of mfecllon
Material and Methods
Selection of 1mmunogemc protems. The protein to be included in vaccine was selected by western blots us1ng vanous strains of S Typh1munum as ant1gens and antisera . Bacteria were •Wn in different conditions (low and high osmolarity, low iron, low pH, ... ) to ensure that the ~eted protein would be expressed in various phases of infection. The antisera used to detect nunogenic proteins were recovered from over a hundred of animals that survived episodes 1ical salmonellosis in various herds. The selected protein (p 37) was recognized by all antisera j was expressed in al types of growth conditions. rification of protein. The selected protein was sequenced and cloned into E. coli M 15 using R®2.1 ::gapAREZ as vector. Using the histidine tail the protein was purified by affinity ·omatography (FPLC).
;rospheres production. The selected matrix was a co-polymer of ( poly (DL-Iactic-co-glycolic) d) (PLGA), a non toxic, non teratogenic, FDA approved molecule. The delivery rates are 1trolled by the relative proportion of copolymers. The end products of this polymer are C02 0 . Moreover, it is known that 11 j.Jm and less microspheres are well absorbed by intestinal Is at Payers patches level (Tabata et al., 1996) . This compound also possesses adjuvant >perties (lgartua et al., 1998) . The P37 protein was incorporated into PLGA in a pre-determined io with co-incorporation of albumin to improve P37 incorporation rates . The resulting :::rospheres were lyophilized until the protection trials.
)tection trial. Groups of 8 cross-bred Salmonella negative pigs were administered orally 2 cc of ::rospheres or PBS (control pigs) at 3 weeks of age. At 7 weeks of age, animals were given lily 10 8 cells of a virulent Salmonella Typhimurium DT 104 strains. Pigs were examined twice jay for 12 days using a pre-determined evaluation grid (the sum of clinical signs scores and 1rrhea scores (on 4 levels of severity each) and then sacrificed. At necropsy, bacterial cultures d Salmonella counts in feces and internal organs were performed. Washes of intestinal mucus ·re also performed and lgA production was assessed using an ELISA, adapted from a ~viously described procedures (Cote et al, 2004 ) . Finally, electron microscopy was done on 1all intestines of necropsied animals to check for the presence of microspheres in intestinal •pts. ~suits imals that received the microsphere vaccine had clearly less clinical signs compared to the ntrol group (figure 1 ). Only one of vaccinated animals showed a mild diarrhea while diarrhea, • en severe, was observed in all control animals. None of vaccinated animals had temperature er 40° C while it was observed in 5 out of 8 control pigs. Although a trend to higher lgA levels ~s observed in vaccinated pigs, no statistical diffence was observed between to groups of 1mals. Electron microscopy revealed the presence of microspheres in intestinal crypts and latine tonsils 2 days after immunization (data not shown) and 12 days after the experimental allenge (figure 2), more than 5 weeks after vaccination. It was not possible to observe ltistically significant reduction of bacterial counts in tissues of both groups of animals. 
Discussion
Use of sub-unit vaccines can be beneficial to avoid undesirable effects seldom seen with live vaccine In addition , when the selected antigen IS embedded within an appropriate matrix, it may be delivered into the host gradually, avoiding repetitive vaccine admintstrat1ons. Results obtained in th1s study suggest that co-polymer of PLGA can be use to protect immunogenic proteins in swine and to slowly deliver the antigens within the intestinal tract. Indeed, even 5 weeks after vaccine administration, it was possible to observe microspheres in the intestinal tract of p1gs suggest1ng that the vaccine will be efficiently delivered for a prolonged period of time. Moreover, the fact that the end products of th1s compounds are non toxic would eliminate any concern related to food safety. S1nce relatively high dosages of bacteria were used to ensure reproduction of clinical s1gns and given the low numbers of an1mals that were used , it was not unexpected to not observe significant difference 1n bactenal counts in various organs. Further studies with different experimental designs will have to be conducted to assess the ability of this vaccine to reduce shedding of Salmonella or to assess cross protection against other serovar.
Conclusion
Use of a subunit slow delivery vaccine composed of the P37 protein embedded within PLGA m1crospheres succeeded in protecting animals against an experimental infection by Salmonella Typh1murium. It is suggested to conduct further research to assess the efficacy of this vaccine to protect animals against the disease in field conditions or to reduce the carriage in sub-clintcal mfections.
